NSRX Nasus Pharma Ltd.
$3.40▲ +1.64%
Healthcare
Other
Volume 4.2K
Avg Volume (10D) 8.1K
Key Metrics & Fundamentals
Market Cap
$39.88M
P/E Ratio
–
Div Yield
–%
52W Range
1.98 - 9.50
% vs 50 MA
-0.70%
% vs 200 MA
-20.47%
RSI-14
41.4
MACD Histogram
-0.0900
Beta (1Y vs SPY)
0.82
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 11:30 AM
Nasus Pharma Files $50 Million Shelf Registration
MT Newswires · Sep 1, 2026 9:56 PM
NSRX: First Half 2026 Financial Results
Zacks Small Cap Research · Aug 21, 2026 11:00 AM
Nasus Pharma Announces Transition of Chief Financial Officer
GlobeNewswire · Aug 19, 2026 11:00 AM
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 17, 2026 12:14 PM
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
GlobeNewswire · Jul 28, 2026 11:30 AM
OTC Markets Life Sciences Investor Forum: Dan Teleman, CEO, and Eyal Rubin, SVP and CFO, of Nasus Pharma with Zacks SCR's John Vandermosten, CFA
Zacks Small Cap Research · Jul 7, 2026 10:42 AM
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
GlobeNewswire · Jun 26, 2026 12:35 PM
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
GlobeNewswire · Jun 23, 2026 12:35 PM
NSRX: NS002 June KOL Event
Zacks Small Cap Research · Jun 22, 2026 12:04 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
No Reddit posts found for NSRX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.